title: GH deficiency in adults: an epidemiological approach.
abstract: OBJECTIVE
  The prevalence of adult onset GH deficiency (GH-D) is poorly documented. Epidemiological data are now required to estimate the financial cost of GH treatment in adults. The aim of the present study was to estimate the prevalence of GH-D, from a cohort of 1652 adult patients with hypothalamo-pituitary diseases.
  
  
  METHODS
  The hormonal status of all patients presenting with pituitary diseaseand observed during the year 1994 in 15 endocrine units was retrospectively analyzed, irrespective of the date of disease onset, of the nature and date of pituitary investigations, and whether or not they included specific testing of the GH axis. Of the whole population of 1652 patients, a selected group (RG2) was chosen after exclusion of patients with active acromegaly (n=1414).
  
  
  RESULTS
  GH stimulation tests had been performed in 549 patients of the RG2 group and a documented GH-D was found in 301. A relationship between the value of the GH peak and the number of pituitary deficits was evaluated. For instance, it was shown that 93% of patients with three deficits had GH-D. These results constituted the basis for estimating the number of GH-D in the group of untested patients. The number of GH-D deduced from the number of established GH-D (n=301) and from the number of GH-D hypothesized from other pituitary deficits (n=406) was 707 cases. Prevalence and annual incidence were calculated from data recorded in a referral center with a well-defined catchment area, Marseilles (Bouches du Rhône department). We projected a prevalence of 2638 for France and an annual incidence of 12 GH-D per million of the adult population.
authors.affiliation: Centre de Médecine Nucléaire, Lyon, France.
authors.forename: G
authors.initials: G
authors.lastname: Sassolas
authors.forename: F B
authors.initials: FB
authors.lastname: Chazot
authors.forename: P
authors.initials: P
authors.lastname: Jaquet
authors.forename: I
authors.initials: I
authors.lastname: Bachelot
authors.forename: P
authors.initials: P
authors.lastname: Chanson
authors.forename: C C
authors.initials: CC
authors.lastname: Rudelli
authors.forename: J P
authors.initials: JP
authors.lastname: Tauber
authors.forename: H
authors.initials: H
authors.lastname: Allannic
authors.forename: J
authors.initials: J
authors.lastname: Bringer
authors.forename: N
authors.initials: N
authors.lastname: Roudaut
authors.forename: V
authors.initials: V
authors.lastname: Rohmer
authors.forename: P
authors.initials: P
authors.lastname: Roger
authors.forename: J L
authors.initials: JL
authors.lastname: Latapie
authors.forename: P
authors.initials: P
authors.lastname: Reville
authors.forename: M
authors.initials: M
authors.lastname: Leutenegger
mesh_terms: D000328:Adult; D015331:Cohort Studies; D005260:Female; D005602:France / Q000453:epidemiology; D019382:Human Growth Hormone / Q000172:deficiency* / Q000627:therapeutic use; D006801:Humans; D007027:Hypothalamic Diseases / Q000150:complications / Q000453:epidemiology; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010900:Pituitary Diseases / Q000150:complications / Q000453:epidemiology
chemical_list: D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I